Disrupted Healthcare – Global Deals and Investments – 29 Transactions This Week

VC Deals (12 deals, $210M)

Aptinyx Inc., an Evanston, Ill.-based developer of modulators of the N-methyl-D-aspartate receptor for the treatment of neurological disorders, has raised $65 million in Series A funding. New Leaf Venture Partnersled the round, and was joined by Frazier Healthcare Partners, Longitude Capital, and Osage University Partners. Also participating were investors who helped Aptinyx spin out of VC-backed Naurex last year: Adams Street Partners, LVP Life Science Ventures, PathoCapital, Goudy Park Capital, Beecken Petty O’Keefe & Co. and Northwestern University

Evariant, a Farmington, Conn.-based healthcare CRM and analytics solution built on Salesforce, has raised an undisclosed amount of new Series C funding from McKesson Ventures and Salesforce Ventures. Existing backers include Health Enterprise Partners, Lightspeed Venture Partners and Goldman Sachs

Simplee, a Palo Alto, Calif.-based platform that lets patients track and pay medical bills, has raised $20 million in Series C funding. Social Capital led the round, and was joined by American Express Ventures and return backers 83North and Heritage Group

OxStem, an Oxford University spinout focused on designing stem cell drugs to treat age-related diseases, has raised £16.9 million in new VC funding. No investor information was disclosed

G1 Therapeutics, a Chapel Hill, N.C.-based developer of small molecules for use in cancer therapy and biodefense applications, has raised $47 million in third-round funding. Cormorant Asset Management led the round, and was joined by Aju IB Investment, Cowen Private Investments, Franklin Templeton Investments, Rock Springs Capital and return backers Eshelman Ventures, Hatteras Venture Partners, Lumira Capital, MedImmune Ventures, Mountain Group Capital, RA Capital and Tavistock Life Sciences

Pillar Biosciences Inc., a Boston-based developer of clinical oncology testing solutions, has raised $18 million in new finding from ORI Healthcare Fund

EndoStim Inc., a St. Louis-based developer of a neurostimulation therapy device for gastroesophageal reflux disease, has raised $25 million in Series D funding. Endeavour Vision led the round, and was joined by Wellington Partners, GIMV and return backer Santé Ventures

Medal, a San Francisco-based online platform for unifying medical records, has raised $3.78 million in new VC funding, according to a regulatory filing. No investors were disclosed

EnBiotix Inc., a Cambridge, Mass.-based bioengineering startup focused on combatting drug-resistant and drug-tolerant bacterial infections, has raised an undisclosed amount of Series A funding from backers like Wired Holdings Investment Corp. and Apeiron Holdings Ltd

Livongo, the mobile-enabled diabetes management company, has raised $5 million strategic investment from Humana to support the company’s growth

Evariant, which offers healthcare providers a platform to analyze data, execute marketing campaigns, and improve patient engagement, has received an undisclosed investment from McKesson Ventures and Salesforce Ventures

Mental and behavioral health video visit company Regroup Therapy has raised $1.8 million in a round led by Hyde Park Angels with participation from OCA Ventures, Impact Engine, New Stack Ventures, Wasson Enterprise, and MD Angels

PE Deals (7 deals)

Aptuit, a Greenwich, Conn.-based portfolio company of Welsh, Carson, Anderson & Stowe, has agreed to acquire Kuecept Ltd., a London-based provider of technical expertise in CRO services supporting preclinical drug development. No financial terms were disclosed

PAI Partners is in advanced talks to acquire Ethypharm, a French drug developer focused on treatment of pains and addictions, for around €750 million from Astorg Partners

Warburg Pincus reportedly has acquired an undisclosed stake in UIB, a Shanghai-based gynecological and pediatric hospital chain, for an undisclosed amount. No financial terms were disclosed

Epic Health Services Inc., a Dallas-based portfolio company of  Webster Capital, has acquired Rehabilitation Associates, a Virginia Beach, Va.-based private pediatric therapy provider. No financial terms were disclosed

Iovate Health Sciences International Inc., a Canadian provider of nutrition and weight-loss products has received takeover bids from such suitors as CDH Investments, Hony Capital, Kelso & Co. and Xiwang Group Co., according toBloomberg. The deal could value Iovate, maker of MuscleTech, at upwards of $1 billion

Travel Nurse Across America, a North Little Rock, Ark.-based healthcare staffing firm focused on providing travel nurses to hospitals and healthcare facilities, has raised an undisclosed amount of private equity funding fromGridiron Capital

Advanced Medical Personnel Services Inc., a Port Orange, Fla.-based portfolio company of Clearview Capital, has acquired Rise Medical Staffing LLC, a Sacramento, Calif.-based provider of travel nurse staffing solutions to hospitals and other healthcare facilities. No financial terms were disclosed

IPO Deals (6 deals)

Nant Health LLC, a Culver City, Calif.-based personalized healthcare company led by Patrick Soon-Shiong, has filed for a $92 million IPO. It plans to trade on the Nasdaq under ticker symbol NH, with Jefferies and Cowen & Co. serving as lead underwriters. The company reports a $72 million net loss on $58 million in revenue for 2015. Shareholders include Allscripts Healthcare Solutions, Celgene Corp., BlackBerry Corp., Kuwait Investment Authority and Verizon Ventures

Spring Bank Pharmaceuticals Inc., a Hopkinton, Mass.-based developer of drugs based on a proprietary small molecule nucleic acid hybrid, raised $11 million in its IPO. The company priced 0.9 million shares at $12 per share, compared to already-reduced plans that had the company offering 1.15 million shares at between $12 and $14 per share. The pre-revenue company will trade on the Nasdaq under ticker symbol SBPH

Merus BV, a Dutch immuno-oncology company focused on bispecific antibody therapeutics, has set its IPO terms to 4.33 million shares being offered at between $14 and $16 per share. It would have an initial market cap of approximately $214 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol MRUS, with Citigroup and Jefferies serving as lead underwriters. Merus has raised over $170 million in VC funding from firms like Novartis Bioventures (13.7% pre-IPO stake), Bay City Capital (13.7%), Aglaia Oncology Fund (11%), Johnson & Johnson (10.6%), Pfizer Inc. (9.1%), Sofinnova Venture Partners (8.2%), Novo AS (7.8%), Baker Brothers Life Sciences (7.2%) and Cooperatief LSP (6.8%)

Oncobiologics, a Cranbury, N.J.-based developer of biosimilar therapeutics, has cut its proposed IPO terms to 5.8 million shares being offered at $6 per share, compared to earlier plans to offer 5 million shares at between $11 and $13 per share. The company plans to trade on the Nasdaq under ticker symbol ONS, with Jefferies and Barclays serving as lead underwriters.Oncobiologics has raised over $43 million in VC funding, from firms like Perceptive Advisors,Cormorant Global Healthcare Master Fund, Longwood Capital Partners, venBio Select Fund, Proximare Lifesciences Fund, OSSB Pharma Fund and MIH Fund

Clearside Biomedical Inc., an Alpharetta, Ga.-based developer of therapies to treat blinding diseases of the eye, has set its IPO terms to 4 million shares being offered at between $14 and $16 per share. It would have an initial market cap of approximately $244 million, were it to price in the middle of its range. The pre-revenue company plans to trade on the Nasdaq under ticker symbol CLSD, with RBC Capital Markets serving as lead underwriter. Shareholders include Hatteras Venture Partners (28.4% pre-IPO stake), RMI Investments (12.5%), Santen Pharmaceutical Co. (9.2%), GRA Venture Fund (7.2%), Aju IB Investment, Cormorant Asset Management, Perceptive Advisors and Rock Springs Capital Management

Viamet Pharmaceuticals Holdings, a Durham, N.C.-based developer of inhibitors of validated metalloenzymes, has postponed an IPO that had been scheduled to price this week. The company had filed to sell 5.7 million shares at between $14 and $16 per share, after having previously filed for a $75 million IPO in 2014 that was withdrawn later that same year. Viamet has raised over $150 million in VC funding from firms like Novartis Bioventures (12.9% pre-IPO stake), Lilly Ventures (11.3%), Hatteras Venture Partners (7.8%) and Intersouth Partners (6.3%)

Other Deals (4 deals)

BTG (LSE: BTG) has agreed to acquire Galil Medical, an Israeli developer of oncology cryoablation technology, for upwards of $110 million (including $84.5m in cash). Galil Medical had raised around $68 million in VC funding from firms like Investor Growth Capital, Elron Electronic Industries, Thomas McNerney & Partners and The Vertical Group

The Medicines Co. (Nasdaq: MDCO) has agreed to sell some of its cardiovascular assets to Italy’s Chiesi Farmaceutici SpA for up to $792 million (including $260m in cash at closing)

Ardian is beginning to discuss a dividend recap for German specialty pharma company Riemser, as the first step of what would become a sale process, according toReuters. Riemser generates around €300 million in annual revenue

DePuy Orthopaedics, a unit of Johnson & Johnson (NYSE: JNJ), has acquiredBioMedical Enterprises Inc., a San Antonio, Texas-based maker of orthopedic implants for small bone fixation, from Cross Atlantic Partners andCamden Partners. No financial terms were disclosed. BME was represented on the deal by England & Co

Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg, MobiHealthNews

Julien de Salaberry @ The Propell Group

#healthtech #asia #deals #investments #healthcare